This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Calendar: Key Dates for November

BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for November:

Nov. 2
Dendreon (DNDN) third-quarter earnings. Will Provenge sales recover?

Nov. 3-5
North American Cystic Fibrosis Conference: Vertex Pharmaceuticals (VRTX) presenting Kalydeco data.

Nov. 4-8
American Association for the Study of Liver Disease (AASLD) annual meeting. Key presentations of hepatitis C drug data from Pharmasset (VRUS), Bristol-Myers Squibb (BMY), Vertex Pharmaceuticals, Merck (MRK), Johnson & Johnson (JNJ) and others.

Nov. 5-9
American College of Rheumatology (ACR) annual meeting.

Nov. 7
Roche (RHHBY) analyst/investor meeting.
American Society of Hematology (ASH) annual meeting research abstracts released: Ariad Pharmaceuticals (ARIA), Celgene (CELG), YM BioSciences (YMI).

Nov. 10
Merck analyst/investor meeting.

Nov. 11
FDA approval decision for Alimera Sciences (ALIM - Get Report) and pSivida's (PSDV - Get Report) Iluvien for diabetic macular edema.

Nov. 12-16
American Heart Association Scientific Sessions: Aastrom Biosciences (ASTM), Amarin (AMRN - Get Report).
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Nov. 13
FDA approval decision for IntelGenx's (IGXT.OB) CPI-300 anti-depressant.

Nov. 16
FDA advisory panel convened to review Salix Pharmaceuticals' (SLXP) Xifaxan for irritable bowel syndrome with diarrhea.

Nov. 18
FDA approval decision for Regeneron Pharmaceuticals' (REGN) Eyelea for age-related macular degeneration.

Nov. 27
FDA approval decision for Transcept Pharmaceuticals' (TSPT - Get Report) Intermezzo sleeping pill.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
TSPT $30.65 -2.79%
ALIM $4.59 0.00%
AMRN $2.41 0.00%
ASTM $3.76 -3.34%
PSDV $4.03 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs